Chongqing Zhifei Biological Products Co., Ltd. (300122)

Chongqing Zhifei Biological Products Co., Ltd. (300122)

Chongqing Zhifei Biological Products Co., Ltd. invested in the biological products industry in 2002 with a registered capital of 1.6 billion yuan, with nearly 3000 employees and assets of 13.6 billion yuan. In 2019, the company realized operating income of 10.59 billion yuan. In September, 2010, it was listed on Shenzhen Stock Exchange (Stock Code: 300122), becoming the first private vaccine enterprise listed on the gem, five wholly-owned subsidiaries and one participating subsidiary, among which Beijing Zhifei green bamboo biopharmaceutical Co., Ltd. (hereinafter referred to as "Beijing Zhifei green bamboo") and Anhui zhifeilong Kema bio Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui zhifeilongke Ma") It is a high-tech enterprise. Zhifei biology is a high-tech enterprise integrating vaccine, biological product research and development, production, sales, promotion, distribution and import and export. The main human vaccine is the seven strategic emerging industries of the country, with a broad development prospect. The products now sold include recombinant Mycobacterium tuberculosis fusion protein (EC) (Yika;), Haemophilus influenzae B vaccine (xiphoebe;), acyw135 meningococcal polysaccharide vaccine (alliance?), Mycobacterium cow for injection (MICA;), group a group C meningococcal polysaccharide binding vaccine (mengnacan?), and the company uniformly sells the products authorized by mosartan All imported vaccines, such as tetravalent human papillomavirus vaccine (Saccharomyces cerevisiae), 9-valent human papillomavirus vaccine (Saccharomyces cerevisiae), oral live vaccine for reducing rotavirus virus (Vero cell), 23 valent pneumococcal polysaccharide vaccine, hepatitis A inactivated vaccine (human diploid cell) and so on.

Through the two wheel drive mode of "technology + market", the company has formed a good circulation mechanism of R & D, mutual promotion and mutual transformation of market, accelerated the process of vaccine product from R & D to realizing market value transformation, and gradually formed a core competitive power with unique and leading market.

>> Polycore Tubing